Where will Cipla share price be in the next 3 years?

Cipla is highlighted for its positive long-term outlook, anchored by generic Ventolin approval from its US facility targeting an estimated US$ 1.5 billion albuterol inhaler market. The company has strengthened its portfolio through differentiated launches across respiratory, diabetes, urology and antimicrobial resistance segments, alongside partnerships with Eli Lilly for obesity drug Yurpeak, Mannkind for inhaled insulin Afrezza, and rights to Pfizer's established brands. Cipla plans 40 to 50 US product filings over the next three years and is building a biosimilars presence through its JV with Kemwell.